What is Betterhumans?
Betterhumans operates at the intersection of advanced biotechnology and public health, focusing on the reduction of disease risk through rigorous scientific inquiry. The organization is deeply involved in high-impact fields such as stem cell research and gene-editing experiments, which are designed to delay the aging process and rejuvenate vital organ systems. By maintaining a commitment to transparency and accessibility, Betterhumans distinguishes itself through a unique model that shares findings under a Creative Commons Public Patent License. This approach ensures that the fruits of their research are not siloed, but rather translated into practical, safe, and widely available applications for the general public, guided by a distinguished scientific advisory board.
How much funding has Betterhumans raised?
Betterhumans has raised a total of $18K across 1 funding round:
Debt
$18K
Debt (2021): $18K with participation from PPP
Key Investors in Betterhumans
PPP
Public-Private Partnership
What's next for Betterhumans?
The infusion of capital marks a pivotal transition for Betterhumans as it moves from foundational research into more intensive development phases. With the recent backing, the organization is expected to scale its laboratory operations and expand its portfolio of clinical studies. Strategic priorities will likely include the refinement of gene-editing protocols and the acceleration of stem cell therapies that have shown promise in early-stage trials. As the organization continues to navigate the complexities of biomedical innovation, the focus will remain on maintaining the integrity of its open-access research model while simultaneously building the infrastructure necessary to bring life-extending technologies to market. This growth trajectory suggests a long-term commitment to transforming the landscape of human health and longevity.
See full Betterhumans company page
